RecruitingEarly Phase 1NCT06411678

Application of 68GA-labeled CD73 Targeting Probe PET/CT Imaging in the Diagnosis of Breast Cancer

Sponsor

Peking Union Medical College Hospital

Enrollment

50 participants

Start Date

May 10, 2024

Study Type

INTERVENTIONAL

Conditions

Breast Cancer

Summary

The investigators plan to conduct a 68Ga-DOTA-dPNE PET/CT imaging study in breast cancer patients to observe the binding of the tracer to tumor lesions and evaluate CD73 expression. As part of the study design, a subset of patients will initially undergo dynamic PET/CT imaging to evaluate the safety profile and pharmacokinetic distribution of the radiotracer in vivo. Subsequently, static PET/CT imaging will be performed on additional patients to assess the diagnostic effectiveness of 68Ga-DOTA-dPNE. Imaging results will be correlated with relevant clinical indicators to evaluate the potential of this tracer in diagnosing breast cancer, guiding therapeutic decisions, and predicting responses to targeted therapies.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 70 Years

Plain Language Summary

Simplified for easier understanding

This study uses a specialized PET/CT scan with a radioactive probe that targets a protein called CD73 to help diagnose and image breast cancer. CD73 is overexpressed in some cancers, and this imaging technique may improve detection and staging. **You may be eligible if...** - You are a female aged 18 or older with suspected or confirmed breast cancer - You have at least one measurable tumor seen on imaging - You have not previously received radiation or chemotherapy for this cancer - Your expected survival is at least 12 weeks - You are able to lie flat for 30 minutes for the scan **You may NOT be eligible if...** - You have serious liver or kidney problems - You are pregnant, breastfeeding, or plan to become pregnant during the study - You have claustrophobia or other psychiatric conditions that prevent scanning - You cannot provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUG68GA-DOTA-dPNE

Patients with breast cancer receive intravenously 68GA-DOTA-dPNE followed by PET/CT after 40min of injection

Locations(1)

PUMCH

Dongcheng, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06411678

Related Trials

Genomic Services Research Program

NCT025959571 location

A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer

NCT06103864316 locations

A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)

NCT070671381 location

Sodium-glucose Transporter Type 2 Inhibition in Anthracycline-related Cardiotoxicity

NCT070707652 locations

Social and Environmental Determinants of Breast Cancer Survivorship: the Black Breast Cancer Survivor's Intervention (BBCSI)

NCT068852031 location